Bioventus Management
Management criteria checks 4/4
Bioventus' CEO is Rob Claypoole, appointed in Jan 2024, has a tenure of 2.67 years. total yearly compensation is $4.30M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $2.20M. The average tenure of the management team and the board of directors is 3.4 years and 5.6 years respectively.
Key information
Rob Claypoole
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 19.17% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.4yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Narrative Update • Sep 03
BVS: Fair Value View Will Rely On Steady Margins And P/E
Analysts now view Bioventus as fairly valued at about $15 per share, up from roughly $13, citing updated assumptions for revenue growth, profit margins, the discount rate, and future P/E that together support a higher long term price target. What’s in the News for Bioventus Bioventus has started a review of multiple strategic alternatives after receiving an unsolicited acquisition proposal and several additional expressions of interest, with Latham & Watkins LLP advising the company on the process.
Narrative Update • Aug 20
BVS: Potential Sale Review And 2026 Outlook Will Support Further Upside
Analysts have increased their price target on Bioventus to $17.60 from $14.80, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E, which together support a higher valuation framework. What’s in the News for Bioventus Bioventus is reviewing multiple strategic alternatives after receiving an unsolicited acquisition proposal and additional expressions of interest, with Latham & Watkins LLP engaged as legal adviser.
Narrative Update • Aug 06
BVS: Reaffirmed 2026 Sales Outlook Will Support A Higher Share Price
Analysts have raised their price target for Bioventus from $16.00 to $18.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What’s in the News for Bioventus Bioventus reaffirmed its earnings guidance for the twelve months ending December 31, 2026, maintaining the 2026 financial outlook that was first issued on May 6, 2026.Seeking Alpha • Jul 07
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Summary Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments. The 2027 Hospital Outpatient Prospective Payment System and ASC proposed rule are key catalysts for BVS's recent stock surge. Read the full article on Seeking AlphaNarrative Update • Jun 17
BVS: 2026 Sales Guidance Will Support A Higher Share Price
Analysts maintained their $16.00 price target on Bioventus, noting only minor adjustments to assumptions such as the discount rate, revenue growth outlook, profit margin, and future P/E, which were not significant enough to change their overall valuation view. What's in the News for Bioventus Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, indicating expected net sales in the range of $600 million to $610 million.Narrative Update • Jun 03
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.Narrative Update • May 19
BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price
Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).Analysis Article • May 14
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...Narrative Update • May 01
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.Narrative Update • Apr 17
BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside
Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.Narrative Update • Apr 03
BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside
Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.Narrative Update • Mar 19
BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside
Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.Narrative Update • Mar 05
BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential
Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.Narrative Update • Feb 19
BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.Narrative Update • Feb 05
BVS: Fine Tuned Assumptions Will Support Further Upside Potential
Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.Narrative Update • Jan 22
BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside
Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.Narrative Update • Jan 07
BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential
Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.Narrative Update • Dec 20
BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential
Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).Narrative Update • Dec 06
BVS: Earnings Guidance Will Support Continued Upside Potential In Shares
Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.Analysis Article • Nov 26
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative Update • Nov 22
BVS: Earnings Guidance Is Expected To Drive Share Price Higher
Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.Narrative Update • Nov 03
BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025
Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.Narrative Update • Oct 20
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.Narrative Update • Oct 05
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.Analysis Article • Aug 14
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative
NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...Analysis Article • Aug 09
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...New Narrative • May 30
Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets
Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.Analysis Article • May 07
Is Bioventus (NASDAQ:BVS) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 08
Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues
Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Seeking Alpha • Jan 05
Bioventus: Amply Rewarded For Recent Progress
Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Aug 12
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 27 2026 | n/a | n/a | US$54m |
| Mar 28 2026 | n/a | n/a | US$28m |
| Dec 31 2025 | US$4m | US$824k | US$23m |
| Sep 27 2025 | n/a | n/a | US$10m |
| Jun 28 2025 | n/a | n/a | -US$731k |
| Mar 29 2025 | n/a | n/a | -US$34m |
| Dec 31 2024 | US$6m | US$780k | -US$36m |
Compensation vs Market: Rob's total compensation ($USD4.30M) is about average for companies of similar size in the US market ($USD3.52M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Claypoole (54 yo)
2.7yrs
Tenure
US$4,299,108
Compensation
Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, U.S for Mlnlycke Healt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$4.30m | 0.20% $ 2.2m | |
| Senior VP & CFO | 4.5yrs | US$1.90m | 0.26% $ 2.9m | |
| Senior VP | 9.1yrs | US$1.41m | 0.22% $ 2.5m | |
| Senior Vice President of Operations | 2.9yrs | no data | no data | |
| Vice President of Investor Relations & Treasurer | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 6.1yrs | no data | 0.094% $ 1.0m | |
| Senior VP & Chief Human Resources Officer | 3.4yrs | no data | no data | |
| Senior VP & GM of Surgical | 1.8yrs | no data | no data |
3.4yrs
Average Tenure
60.5yo
Average Age
Experienced Management: BVS's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$4.30m | 0.20% $ 2.2m | |
| Independent Director | 6yrs | US$275.00k | 0.22% $ 2.4m | |
| Independent Director | 3.7yrs | US$290.00k | 0.16% $ 1.8m | |
| Independent Director | 6yrs | US$215.00k | 0.17% $ 1.9m | |
| Independent Chairman of the Board | 6yrs | US$380.00k | 0.44% $ 4.8m | |
| Independent Director | 6yrs | US$277.50k | 0.17% $ 1.9m | |
| Independent Director | 6yrs | US$300.00k | 0.20% $ 2.2m | |
| Independent Director | 5.2yrs | US$290.00k | 0.16% $ 1.8m | |
| Independent Director | 6yrs | US$245.00k | 0.064% $ 712.6k | |
| Independent Director | 4.9yrs | US$282.50k | 0.16% $ 1.8m | |
| Independent Director | 4.7yrs | US$280.00k | 0.11% $ 1.3m | |
| Independent Director | less than a year | no data | no data |
5.6yrs
Average Tenure
59.5yo
Average Age
Experienced Board: BVS's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 21:41 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2026/06/27 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bioventus Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Kyle Rose | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |